Scholarlink

<p>Numerous studies assessing the risk of atherosclerotic cardiovascular disease (ASCVD) in lichen planus, a chronic inflammatory disease, have been limited by sample size and have included only a limited evaluation atherogenic index of plasma (AIP). This study aimed to compare the predisposition to atherothrombosis in patients with lichen planus and controls (consisting of individuals without systemic inflammatory or metabolic disease) using the AIP and related laboratory parameters. In this context, a comparative analysis of routine hematological and biochemical parameters (urea, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting blood glucose, uric acid) along with serum lipid levels (triglyceride (TG), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C)), AIP, hemoglobin A1C (HbA1c), C-reactive protein (CRP), thyroid-stimulating hormone (TSH), ferritin, and erythrocyte sedimentation rate (ESR) was planned. This retrospective case-control study included a total of 200 patients, consisting of 100 patients diagnosed with lichen planus and 100 controls. The risk of ASCVD was assessed based on patients demographic data and blood parameters. A cut-off value for AIP was determined in patients with lichen planus. The AIP value was found to be significantly higher in the lichen planus patient group compared to the control group (p &lt; 0.05) and an AIP cut-off value of 0.528 was determined, which may indicate an increased atherogenic tendency in patients with lichen planus. In addition, ALT, total cholesterol, triglyceride, VLDL-C, LDL-C, ESR, hemoglobin and hematocrit values were significantly higher in the lichen planus patient group compared to the control group (p &lt; 0.05). In contrast, fasting blood glucose, urea, creatinine, AST, HDL-C, uric acid, HbA1c, CRP, TSH, ferritin, white blood cell count (WBC), percentage of neutrophils (NEUT%), percentage of Lymphocytes (LYM%) and Platelet count (PLT) values did not show a significant difference (p &gt; 0.05). The significant elevation of AIP and lipid profile parameters in lichen planus patients compared to controls suggests a potential link between chronic inflammation and subclinical atherogenesis. This finding aligns with prior studies reporting increased cardiovascular risk in chronic inflammatory dermatoses. The role of immune-mediated pathways and systemic inflammatory burden in altering lipid metabolism may partly explain this association. Thus, assessing AIP alongside routine lipid panels in patients with lichen planus may help identify those at higher cardiometabolic risk earlier in the disease course.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessment of increased risk of atherothrombotic cardiovascular disease in patients with lichen planus: a case-control study

  • 期刊论文

  • 发表日期：

    2026年7月11日

查看全文
  • Altay Esra,
  • Temiz Selami Aykut,
  • Topaloğlu Ahmet Furkan,
  • Kozak Hasan Hüseyin,
  • Dursun Recep

摘要

Numerous studies assessing the risk of atherosclerotic cardiovascular disease (ASCVD) in lichen planus, a chronic inflammatory disease, have been limited by sample size and have included only a limited evaluation atherogenic index of plasma (AIP). This study aimed to compare the predisposition to atherothrombosis in patients with lichen planus and controls (consisting of individuals without systemic inflammatory or metabolic disease) using the AIP and related laboratory parameters. In this context, a comparative analysis of routine hematological and biochemical parameters (urea, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting blood glucose, uric acid) along with serum lipid levels (triglyceride (TG), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C)), AIP, hemoglobin A1C (HbA1c), C-reactive protein (CRP), thyroid-stimulating hormone (TSH), ferritin, and erythrocyte sedimentation rate (ESR) was planned. This retrospective case-control study included a total of 200 patients, consisting of 100 patients diagnosed with lichen planus and 100 controls. The risk of ASCVD was assessed based on patients demographic data and blood parameters. A cut-off value for AIP was determined in patients with lichen planus. The AIP value was found to be significantly higher in the lichen planus patient group compared to the control group (p < 0.05) and an AIP cut-off value of 0.528 was determined, which may indicate an increased atherogenic tendency in patients with lichen planus. In addition, ALT, total cholesterol, triglyceride, VLDL-C, LDL-C, ESR, hemoglobin and hematocrit values were significantly higher in the lichen planus patient group compared to the control group (p < 0.05). In contrast, fasting blood glucose, urea, creatinine, AST, HDL-C, uric acid, HbA1c, CRP, TSH, ferritin, white blood cell count (WBC), percentage of neutrophils (NEUT%), percentage of Lymphocytes (LYM%) and Platelet count (PLT) values did not show a significant difference (p > 0.05). The significant elevation of AIP and lipid profile parameters in lichen planus patients compared to controls suggests a potential link between chronic inflammation and subclinical atherogenesis. This finding aligns with prior studies reporting increased cardiovascular risk in chronic inflammatory dermatoses. The role of immune-mediated pathways and systemic inflammatory burden in altering lipid metabolism may partly explain this association. Thus, assessing AIP alongside routine lipid panels in patients with lichen planus may help identify those at higher cardiometabolic risk earlier in the disease course.